The role of angiogenesis in prostate development and the pathogenesis of prostate cancer

被引:36
作者
Hrouda, D
Nicol, DL
Gardiner, RA [1 ]
机构
[1] Royal Brisbane Hosp, Dept Urol, Brisbane, Qld 4029, Australia
[2] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld 4102, Australia
[3] Univ Queensland, Dept Surg, Brisbane, Qld, Australia
来源
UROLOGICAL RESEARCH | 2003年 / 30卷 / 06期
关键词
angiogenesis; prostate; prostate cancer; VEGF;
D O I
10.1007/s00240-002-0287-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
New vessel formation, a highly-regulated, active process commencing in the embryo and evident notably during the pubertal growth spurt, is essential for normal prostate development. Reactivation of this process in response to physiological stimuli, particularly hypoxia in mature tissues, occurs with new vessels forming principally from stromal components. Although angiogenesis is complex, putatively involving a multitude of angiogenic factors and inhibitors, there is powerful evidence of the importance of the VEGF system in the development of both the normal prostate and prostate cancer. Recent advances include an understanding of how castration acts through the VEGF system to inhibit angiogenesis. Stromal-endothelial and epithelial-endothelial interactions are just beginning to be investigated. A better understanding of how physiological angiogenesis is controlled should help to provide further insights into the mechanism of disregulated angiogenesis in tumours. Ultimately, new antiangiogenic agents are likely to find a role in the management of patients with prostate cancer.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 76 条
[1]  
Bok RA, 2001, CANCER RES, V61, P2533
[2]  
Borgström P, 1998, PROSTATE, V35, P1
[3]   Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting [J].
Borre, M ;
Offersen, BV ;
Nerstrom, B ;
Overgaard, J .
BRITISH JOURNAL OF CANCER, 1998, 78 (07) :940-944
[4]  
BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO
[5]  
2-6
[6]  
Burchardt M, 2000, PROSTATE, V43, P184, DOI 10.1002/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO
[7]  
2-6
[8]  
Campbell CL, 1999, INT J CANCER, V80, P868, DOI 10.1002/(SICI)1097-0215(19990315)80:6<868::AID-IJC12>3.3.CO
[9]  
2-T
[10]  
CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO